Bradford Smith

Mr. Smith is currently the Chief Financial Officer of Homology Medicines, Inc. (NASDAQ: FIXX), which he joined in 2017. Prior to joining Homology, he served as Chief Financial Officer of Ocular Therapeutix, Inc., (NASDAQ: OCUL) where he led the company’s strategic financings, including an IPO and subsequent follow-on offerings, and completed a development and commercialization deal with a major biopharmaceutical company. Previously, Mr. Smith has also served as Chief Financial Officer of OmniGuide Inc,. Mr. Smith holds a B.S. in Biology from Tufts University and an M.B.A. from the Whittemore School at the University of New Hampshire.